Neurogene (NGNE)
NASDAQ:NGNE
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 925.00K | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -3.19M | $ -2.32M | $ -3.26M | $ -3.20M | $ -42.26M |
| Operating Income | $ -103.21M | $ -82.61M | $ -55.58M | $ -56.52M | $ -50.53M |
| EBITDA | $ -103.33M | $ -71.89M | $ -52.29M | $ -51.99M | $ -49.59M |
| Net Income | $ -90.35M | $ -75.14M | $ -36.32M | $ -55.19M | $ -50.52M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 269.01M | $ 312.40M | $ 197.16M | $ 82.02M | $ 70.54M |
| Total Assets | $ 288.60M | $ 335.73M | $ 222.57M | $ 109.27M | $ 101.49M |
| Total Debt | $ 9.89M | $ 12.43M | $ 16.25M | $ 4.69M | $ 6.43M |
| Net Debt | $ -93.95M | $ -124.16M | $ -131.96M | $ -77.33M | $ -64.11M |
| Total Liabilities | $ 23.72M | $ 25.36M | $ 36.55M | $ 10.64M | $ 193.36M |
| Stockholders' Equity | $ 264.89M | $ 310.38M | $ 186.02M | $ 98.63M | $ -91.88M |
| Cash Flow | |||||
| Free Cash Flow | $ -78.36M | $ -71.41M | $ -51.74M | $ -55.05M | $ -64.77M |
| Operating Cash Flow | $ -77.17M | $ -70.60M | $ -51.42M | $ -52.82M | $ -46.40M |
| Investing Cash Flow | $ 14.00M | $ -125.26M | $ 25.64M | $ -2.23M | $ -18.37M |
| Financing Cash Flow | $ 30.43M | $ 184.07M | $ 92.48M | $ 66.53M | $ 51.06M |